The era of enforcement actions targeting large pharmaceutical companies’ off-label promotional practices may be coming to a close, but government lawyers are eyeing a new wave of industry practices for scrutiny and potential prosecution.
Among these are unsupported promotional claims of economic superiority and superior efficacy, manufacturers’ dealings with payers, misrepresentation of scientific studies, and manipulation of the average sales price system, federal prosecutors...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?